{"id":"mtx-therapy","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Myelosuppression (anemia, leukopenia, thrombocytopenia)"},{"rate":"10-30","effect":"Mucositis / stomatitis"},{"rate":"20-30","effect":"Nausea and vomiting"},{"rate":"5-15","effect":"Hepatotoxicity"},{"rate":"5-10","effect":"Nephrotoxicity"},{"rate":"5-15","effect":"Neurotoxicity (high-dose)"},{"rate":"10-20","effect":"Alopecia"},{"rate":"10-25","effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL2074706","moleculeType":"Small molecule","molecularWeight":"466.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MTX is a folate antagonist that inhibits dihydrofolate reductase, an enzyme critical for converting dihydrofolate to tetrahydrofolate, which is essential for one-carbon transfer reactions in nucleotide synthesis. This leads to decreased DNA and RNA synthesis, making it effective as both a chemotherapy agent and an immunosuppressant. At lower doses, it also has immunomodulatory effects through adenosine release and inhibition of inflammatory cytokine production.","oneSentence":"Methotrexate inhibits dihydrofolate reductase, blocking folate metabolism and reducing DNA synthesis and cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:01.222Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Osteosarcoma"},{"name":"Breast cancer"},{"name":"Rheumatoid arthritis"},{"name":"Psoriasis"},{"name":"Inflammatory bowel disease"}]},"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT04628767","phase":"PHASE2, PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":249},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT02143414","phase":"PHASE2","title":"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-06-30","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":53},{"nctId":"NCT07498465","phase":"PHASE1","title":"A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-09-10","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia","enrollment":29},{"nctId":"NCT04609046","phase":"PHASE1","title":"Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-24","conditions":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","enrollment":47},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT06985498","phase":"PHASE2","title":"Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-01","conditions":"Acute Lymphobkastic Leukemia","enrollment":40},{"nctId":"NCT07242092","phase":"PHASE4","title":"Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-25","conditions":"Autoimmune Rheumatic Diseases","enrollment":192},{"nctId":"NCT02422641","phase":"PHASE2","title":"Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2015-05","conditions":"Metastatic Breast Cancer, Leptomeningeal Disease","enrollment":16},{"nctId":"NCT07486843","phase":"PHASE4","title":"Preventing Structural Damage in Early Psoriatic Arthritis","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2026-03-16","conditions":"Psoriatic Arthritis (PsA)","enrollment":108},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT05043870","phase":"PHASE4","title":"Combined Immunosuppression for Pediatric Crohn's Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2022-10-10","conditions":"Crohn Disease, Infliximab, Immunosuppression","enrollment":128},{"nctId":"NCT01011920","phase":"PHASE2","title":"Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2009-11","conditions":"Central Nervous System Lymphoma","enrollment":227},{"nctId":"NCT03684980","phase":"EARLY_PHASE1","title":"LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-11-14","conditions":"Central Nervous System Lymphoma","enrollment":58},{"nctId":"NCT04931368","phase":"PHASE3","title":"OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Klinikum Stuttgart","startDate":"2021-06-28","conditions":"Primary Central Nervous System Lymphoma","enrollment":331},{"nctId":"NCT07477691","phase":"PHASE4","title":"Immune Modulation During Palynziq® Treatment in Adults (IMPALA)","status":"NOT_YET_RECRUITING","sponsor":"BioMarin Pharmaceutical","startDate":"2026-03-31","conditions":"Phenylketonuria","enrollment":12},{"nctId":"NCT06918431","phase":"PHASE2","title":"Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-10","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma","enrollment":53},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT03785574","phase":"NA","title":"Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule","status":"RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2018-12-24","conditions":"Hydatidiform Mole, Gestational Trophoblastic Neoplasia","enrollment":30},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT03970096","phase":"PHASE2","title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-11-19","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":"Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated","enrollment":30},{"nctId":"NCT07463937","phase":"","title":"A RWS of SC MTX in Chinese RA Patients","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-09-03","conditions":"Rheumatoid Arthritis (RA)","enrollment":10000},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT04965597","phase":"PHASE2","title":"Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-04-19","conditions":"Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia","enrollment":40},{"nctId":"NCT04384692","phase":"PHASE2","title":"Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-18","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":53},{"nctId":"NCT07454226","phase":"NA","title":"ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Ph-Like, Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT05157971","phase":"PHASE1","title":"Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-03-17","conditions":"B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia","enrollment":24},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":"Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":40},{"nctId":"NCT06177067","phase":"PHASE1","title":"Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-04-19","conditions":"Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":24},{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT06289673","phase":"PHASE4","title":"Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-26","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia","enrollment":850},{"nctId":"NCT06390319","phase":"PHASE2","title":"Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-27","conditions":"T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia","enrollment":100},{"nctId":"NCT04830709","phase":"","title":"Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-15","conditions":"Ovarian Cancer","enrollment":750},{"nctId":"NCT03263572","phase":"PHASE2","title":"Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-11-29","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression","enrollment":90},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":"Acute Myeloid Leukemia","enrollment":1186},{"nctId":"NCT06247787","phase":"PHASE1","title":"A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-02-04","conditions":"Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia","enrollment":36},{"nctId":"NCT07153796","phase":"PHASE2","title":"A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-01-30","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":60},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT02981628","phase":"PHASE2","title":"Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-06-19","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia","enrollment":80},{"nctId":"NCT07176390","phase":"PHASE2","title":"A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Arthritis, Rheumatoid","enrollment":182},{"nctId":"NCT06475235","phase":"PHASE1","title":"Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-10-18","conditions":"Lymphoma, Primary Central Nervous System Lymphoma","enrollment":15},{"nctId":"NCT07228624","phase":"PHASE2","title":"Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-02-04","conditions":"Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":50},{"nctId":"NCT05718583","phase":"NA","title":"Effects of Administration of SCFA in Rheumatoid Arthritis Inadequate Responders","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2023-02-01","conditions":"Rheumatoid Arthritis","enrollment":20},{"nctId":"NCT03147612","phase":"PHASE2","title":"Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-08","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1","enrollment":22},{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT07405255","phase":"PHASE2","title":"Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-01-30","conditions":"Central Nervous System Lymphoma","enrollment":19},{"nctId":"NCT06533748","phase":"PHASE2","title":"Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-01-23","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":128},{"nctId":"NCT05535166","phase":"PHASE2","title":"Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-12-20","conditions":"Medulloblastoma","enrollment":130},{"nctId":"NCT03913559","phase":"PHASE2","title":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-05-14","conditions":"Acute Lymphoblastic Leukemia","enrollment":5},{"nctId":"NCT03710772","phase":"PHASE2","title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-01","conditions":"Mantle Cell Lymphoma","enrollment":51},{"nctId":"NCT04872790","phase":"PHASE1","title":"Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2022-09-02","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia","enrollment":20},{"nctId":"NCT07381556","phase":"PHASE4","title":"Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2025-11-01","conditions":"Alopecia Areata(AA), Alopecia Areata (AA), Alopecia Totalis/Universalis","enrollment":50},{"nctId":"NCT02315326","phase":"PHASE1, PHASE2","title":"Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-12-08","conditions":"Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)","enrollment":93},{"nctId":"NCT06895473","phase":"PHASE2","title":"Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-04","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":26},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT06252870","phase":"PHASE2","title":"Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-07-18","conditions":"Graft Versus Host Disease, Hematologic Malignancy","enrollment":82},{"nctId":"NCT04898894","phase":"PHASE1","title":"Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-11-15","conditions":"Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage","enrollment":37},{"nctId":"NCT00336024","phase":"PHASE3","title":"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-10-22","conditions":"Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified","enrollment":91},{"nctId":"NCT07360340","phase":"","title":"Methotrexate Therapy and High-Resolution CT Chest and Spirometry Test Findings in Patients With Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-12-01","conditions":"Methohexitone Pulmonary Adverse Reaction","enrollment":50},{"nctId":"NCT07352917","phase":"PHASE2","title":"Methotrexate for Severe Vulvar Lichen Sclerosus","status":"RECRUITING","sponsor":"Clinica Dermatologica Arbache ltda","startDate":"2026-01-21","conditions":"Vulvar Lichen Sclerosus","enrollment":12},{"nctId":"NCT07343661","phase":"PHASE4","title":"Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA","status":"ENROLLING_BY_INVITATION","sponsor":"Azienda Ospedaliero Universitaria di Cagliari","startDate":"2025-10-17","conditions":"EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma, Eosinophilic Asthma","enrollment":90},{"nctId":"NCT07338305","phase":"","title":"Methotrexat to Hand Eczema in the BIOSKIN Cohort","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lone Skov","startDate":"2025-11-01","conditions":"Atopic Dermatitis, Contact Dermatitis, Hand Eczema","enrollment":50},{"nctId":"NCT00602667","phase":"PHASE2","title":"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-17","conditions":"Brain and Central Nervous System Tumors","enrollment":293},{"nctId":"NCT03121014","phase":"PHASE2","title":"Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2017-04-24","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":38},{"nctId":"NCT05814627","phase":"PHASE3","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-15","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT00501826","phase":"PHASE2","title":"Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-07-11","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":160},{"nctId":"NCT06229145","phase":"PHASE4","title":"A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2024-03-18","conditions":"Gout","enrollment":262},{"nctId":"NCT07072585","phase":"PHASE2, PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":"Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma","enrollment":1708},{"nctId":"NCT05576051","phase":"","title":"To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-06-04","conditions":"Rheumatoid Arthritis","enrollment":9159},{"nctId":"NCT05761171","phase":"PHASE2","title":"A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2024-01-08","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","enrollment":78},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435},{"nctId":"NCT02611037","phase":"PHASE2","title":"Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2016-03-04","conditions":"Malignant Pleural Mesothelioma, Mesothelioma","enrollment":34},{"nctId":"NCT06387121","phase":"PHASE2","title":"Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-02","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":53},{"nctId":"NCT02881086","phase":"PHASE3","title":"Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment","status":"COMPLETED","sponsor":"Goethe University","startDate":"2016-08","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":1023},{"nctId":"NCT04483466","phase":"PHASE3","title":"Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"George Washington University","startDate":"2023-07-18","conditions":"Investigate the Effect(s) of Methotrexate Treatment on Arthritis Disease Severity","enrollment":150},{"nctId":"NCT01046825","phase":"PHASE2, PHASE3","title":"Mature B-Cell Lymphoma And Leukemia Study III","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2010-09-09","conditions":"Mature B-Cell Lymphoma","enrollment":128},{"nctId":"NCT02553460","phase":"PHASE1, PHASE2","title":"Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-01-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT06590090","phase":"PHASE2","title":"Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment","status":"NOT_YET_RECRUITING","sponsor":"XBiotech, Inc.","startDate":"2026-07-15","conditions":"Rheumatoid Arthritis","enrollment":108},{"nctId":"NCT01424982","phase":"PHASE2","title":"Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-10-05","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission","enrollment":88},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT02066220","phase":"PHASE2, PHASE3","title":"International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2014-06","conditions":"Brain Tumors","enrollment":360},{"nctId":"NCT02251821","phase":"PHASE2","title":"JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2014-10-20","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":61},{"nctId":"NCT07261306","phase":"EARLY_PHASE1","title":"Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis","status":"RECRUITING","sponsor":"Lahore General Hospital","startDate":"2025-08-29","conditions":"Psoriasis","enrollment":75},{"nctId":"NCT05879419","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-05-23","conditions":"Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis","enrollment":2005},{"nctId":"NCT02101853","phase":"PHASE3","title":"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-17","conditions":"Recurrent B Acute Lymphoblastic Leukemia","enrollment":669},{"nctId":"NCT02112916","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-04","conditions":"Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma","enrollment":847},{"nctId":"NCT02003222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-19","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":488},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia","enrollment":5949},{"nctId":"NCT02427620","phase":"PHASE2","title":"Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-03","conditions":"Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma","enrollment":131},{"nctId":"NCT02277444","phase":"PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-12-22","conditions":"Arthritis, Juvenile","enrollment":130},{"nctId":"NCT07227584","phase":"PHASE2","title":"ALL Backbone in AYAs","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-04","conditions":"Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL)","enrollment":67},{"nctId":"NCT02877303","phase":"PHASE2","title":"Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-11-01","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma","enrollment":80},{"nctId":"NCT06128070","phase":"PHASE2","title":"Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-07-16","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":40},{"nctId":"NCT04511702","phase":"PHASE4","title":"Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate","status":"COMPLETED","sponsor":"Amgen","startDate":"2020-10-02","conditions":"Chronic Uncontrolled Gout, Gout, Uncontrolled Gout","enrollment":191},{"nctId":"NCT03779854","phase":"PHASE2","title":"Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-08-29","conditions":"Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":68}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1202,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"MTX therapy","genericName":"MTX therapy","companyName":"NYU Langone Health","companyId":"nyu-langone-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methotrexate inhibits dihydrofolate reductase, blocking folate metabolism and reducing DNA synthesis and cell proliferation. Used for Acute lymphoblastic leukemia (ALL), Osteosarcoma, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}